CORNERSTONE Process Solutions
CORNERSTONE - FASTER TO CLINICAL TRIALS, FASTER TO MARKET
Our novel Cornerstone process solutions are a comprehensive approach of integrated process development services and novel technology designed to improve the robustness and yield of Advanced therapy medicinal products (ATMPs) production, while improving the safety of therapeutic products. CORNERSTONE process solutions aim to help drug-developers overcome critical development bottlenecks in the production and purification of e.g. AAV and other ATMPs, allowing promising new treatments to be brought more rapidly to clinical trials, ultimately delivering medicines sooner to patients.
Pete Gagnon, Chief Scientific Officer at BIA Separations, commented:
Over the coming months, we will introduce additional tools and procedures to help scientists meet the unique challenges they face with bringing new therapeutic classes to clinical trials, and eventually to commercial production. Starting with AAVs, the program will expand to include other viral vectors, exosomes, mRNA, and DNA plasmids, among other emerging prospects.”
Ingo Nagler, Business Development Officer at BIA Separations, said: “The launch of our CORNERSTONE program reflects BIA Separations’ transition from a product supplier to a full-service solutions company for gene therapy.
Our new service responds to an urgent need in the biopharmaceutical industry for turn-key gene therapy production processes, and we believe we are ideally placed to deliver these.”
For more information on our novel CORNERSTONE AAV Process Development Service, please click here.
For more information on our novel CORNERSTONE Exosomes Process Development Service, please click here.
For more information on our novel CORNERSTONE Exosomes Process Development Pack, please click here.